aTyr Pharma

aTyr lays off 60% to fund 2nd go at ph. 3 lung disease trial

Sixty per cent of aTyr's workforce are heading for the exits as the biotech conserves resources for a second shot at success in a type of lung disease.

James Waldron Aug 10, 2026 4:27am

long shot miss basketball hoop fail shoot

aTyr flunks phase 3 lung disease trial, deflating stock

Sep 15, 2025 9:56am

Biotechs shed dead wood from pipelines amid cash crunch

Nov 11, 2022 9:25am

ATyr slashes headcount, cuts costs after ORCA runs aground

May 14, 2018 9:13am